Competitors NameChg %Market Cap Johnson & Johnson1.06%$390.76B Sanofi ADR-1.35%$136.6B Pfizer Inc.1.47%$149.04B Novartis AG ADR-0.21%$216.12B Dr. Reddy's Laboratories Ltd. ADR0.75%$11.08B Amgen Inc.2.28%$162.78B GSK PLC ADR1.16%$73.72B ...
Competitors NameChg %Market Cap Johnson & Johnson -0.18% $397.55B Sanofi ADR 2.51% $146.96B Pfizer Inc. 0.74% $147.01B Novartis AG ADR 0.41% $222.89B Dr. Reddy's Laboratories Ltd. ADR 0.86% $10.8B Amgen Inc. 1.40% $170.06B GSK PLC ADR 0.99% $77.78B Merck & Co. Inc. 0.68% $...
Unlike its competitors—K-CAB (tegoprazan), Fexuclue (fexuprazan), and Jaqbo (zastaprazan)—all of which secured reimbursement pricing, Vocinti never received reimbursement. Despite entering price negotiations, Takeda reportedly found the government’s offer too low to justify launching the drug. ...
Takeda Pharmaceutical Co - ADR Competitors - Telecommunications Equipment Company Price USD Returns 1-YEAR RETURNS 5-year Astrazeneca plc - ADR AZN $77.47 19.38% 12.89% Sanofi - ADR SNY $59.42 27.88% 8.14% Vertex Pharmaceuticals, Inc. VRTX $485.72 18.31% 15.78% Regeneron Pharmaceuticals, Inc. ...
After the remaining competitors defeated Arcade and shut down Murder World, Hazmat urged the survivors to never discuss what occurred during the death match, even after Arcade publicly released video footage online. Months later, several arena survivors tracked Arcade to Baron Helmut Zemo, AKA ...
Takeda and Protagonist Therapeutics, Inc., announced the signing of a worldwide license and collaboration agreement for the development and commercialization of rusfertide, an investigational injectable hepcidin mimetic peptide of the natural...
Benchmark the company against the market with exclusive information on key competitorsRegister your interest Chart Financial activity with access to more key statsRegister your interest Executives NamePositionBoardSinceAge Christophe WeberDirector; Chief Executive Officer; PresidentExecutive Board201558 ...
Competitors Earnings Financials Institutional Ownership Headlines Options Chain SEC Filings Short Interest Social Media Takeda Pharmaceutical MarketRank™ Forecast Analyst Rating Moderate Buy 2.67 Rating Score Upside/Downside 49.9% Upside $24.00 Price Target Short Interest Healthy 0.17% of Float Sold Sho...
Takeda, however, is spending significantly more than its Japanese competitors to buy a profitable, midsized U.S. biotech business. The 15-year-old Millennium had revenues of $528 million in 2007; $265 million came from its U.S. sale... 展开 ...
developments relating to our competitors and our industry; and other statements that are not historical facts. Words such as ‘‘anticipate,’’‘‘believe,’’“contemplate,”‘‘continue,’’‘‘could,’’‘‘estimate,’’‘‘expect,’’“hope,”‘‘intend,’’‘‘...